BSX241220C55000
- 0.00
- 0.000.00%
Boston Scientific Newsroom
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Vivani Medical (VANI) and Merit Medical Systems (MMSI)
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $110
RBC Capital Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $105
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Announces Target Price $110
Morgan Stanley Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Boston Scientific Analyst Ratings
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110
Goldman Sachs Raises Price Target on Boston Scientific to $103 From $102, Maintains Buy Rating
Boston Scientific Is Maintained at Buy by TD Cowen
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $110
TD Cowen Adjusts Price Target on Boston Scientific to $110 From $100, Maintains Buy Rating
Boston Scientific Is Maintained at Overweight by Wells Fargo
Boston Scientific Analyst Ratings
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $107
CICC Initiates Boston Scientific at Outperform With $116 Price Target
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $98
Boston Scientific's Promising Clinical Trials and Innovative Approaches Justify Buy Rating
Boston Scientific Is Maintained at Buy by Canaccord Genuity